Drug Trial Radar · NCT04872101
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
473
Actual
Start
May 25, 2021
Primary completion
Dec 27, 2022
Study completion Jan 6, 2023
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.
Conditions
- Chronic Hand Eczema
Interventions
Delgocitinib creamDrug
Cream for topical application
Cream vehicleDrug
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With IGA-CHE TS at Week 16Time frame: 16 weeks
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
LEO Investigational Site
Brussels, Belgium
LEO Investigational Site
Edegem, Belgium
LEO Investigational Site
Ghent, Belgium
LEO Investigational Site
Kortrijk, Belgium
LEO Investigational Site
Leuven, Belgium
LEO Investigational Site
Loverval, Belgium
LEO Investigational Site
Maldegem, Belgium
LEO Investigational Site
Surrey, British Columbia, Canada
LEO Investigational Site
Vancouver, British Columbia, Canada
LEO Investigational Site
Fredericton, New Brunswick, Canada
LEO Investigational Site
Ajax, Ontario, Canada
LEO Investigational Site
Cobourg, Ontario, Canada
LEO Investigational Site
Etobicoke, Ontario, Canada
LEO Investigational Site
Hamilton, Ontario, Canada
LEO Investigational Site
Toronto, Ontario, Canada
LEO Investigational Site
Waterloo, Ontario, Canada
LEO Investigational Site
Windsor, Ontario, Canada
LEO Investigational Site
Aarhus, Denmark
LEO Investigational Site
Copenhagen, Denmark
LEO Investigational Site
Hellerup, Denmark
LEO Investigational Site
Aachen, Germany
LEO Investigational Site
Bad Bentheim, Germany
LEO Investigational Site
Frankfurt, Germany
LEO Investigational Site
Friedrichshafen, Germany
LEO Invesitgational Site
Hanover, Germany
LEO Investigational Site
Jena, Germany
LEO Investigational Site
Lübeck, Germany
LEO Investigational Site
Mahlow, Germany
LEO Investigational Site
Münster, Germany
LEO Investigational Site
Stuttgart, Germany
LEO Investigational Site
Amsterdam, Netherlands
LEO Investigational Site
Bergen op Zoom, Netherlands
LEO Investigational Site
Breda, Netherlands
LEO Investigational Site
Groningen, Netherlands
LEO Investigational Site
Hoofddorp, Netherlands
LEO Investigational Site
Utrecht, Netherlands
LEO Investigational Site
Bialystok, Poland
LEO Investigational Site
Lublin, Poland
LEO Investigational Site
Rzeszów, Poland
LEO Investigational Site
Warsaw, Poland
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.